Advertisement

Topics

Carcinoid Syndrome Management market is estimated to grow at 7% CAGR by 2022

04:41 EDT 21 Jun 2017 | Topix

Major Key Players are Novartis International AG, Pharmascience Inc. , Omega Laboratories Ltd. , Teva Pharmaceutical Industries Ltd. , Mylan N.V. , " The global Carcinoid Syndrome Management market has been evaluated as average growing market and expected that the market will reach high growth figures in coming years. The global market for carcinoid syndrome management is highly consolidated and very rare number of players constitutes the entire market.

Original Article: Carcinoid Syndrome Management market is estimated to grow at 7% CAGR by 2022

NEXT ARTICLE

More From BioPortfolio on "Carcinoid Syndrome Management market is estimated to grow at 7% CAGR by 2022"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...